PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 203 filers reported holding PDL BIOPHARMA INC in Q2 2016. The put-call ratio across all filers is 2.73 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $15,602,000 | -27.2% | 7,359,385 | +15.0% | 0.00% | -25.0% |
Q3 2016 | $21,445,000 | +13.9% | 6,401,415 | +6.7% | 0.00% | 0.0% |
Q2 2016 | $18,830,000 | -4.3% | 5,996,693 | +1.5% | 0.00% | -20.0% |
Q1 2016 | $19,682,000 | -55.3% | 5,910,486 | -52.5% | 0.01% | -50.0% |
Q4 2015 | $44,026,000 | -31.1% | 12,436,795 | -2.0% | 0.01% | -41.2% |
Q3 2015 | $63,861,000 | -23.4% | 12,696,043 | -2.1% | 0.02% | -15.0% |
Q2 2015 | $83,369,000 | -11.3% | 12,965,652 | -3.0% | 0.02% | -9.1% |
Q1 2015 | $94,015,000 | -0.9% | 13,363,921 | +8.6% | 0.02% | -4.3% |
Q4 2014 | $94,863,000 | +10.0% | 12,303,913 | +6.6% | 0.02% | -4.2% |
Q3 2014 | $86,231,000 | -21.7% | 11,543,595 | +1.4% | 0.02% | -22.6% |
Q2 2014 | $110,199,000 | +15.2% | 11,384,180 | -1.1% | 0.03% | +10.7% |
Q1 2014 | $95,661,000 | +4.7% | 11,511,495 | +6.3% | 0.03% | 0.0% |
Q4 2013 | $91,365,000 | +7.9% | 10,825,279 | +1.8% | 0.03% | -3.4% |
Q3 2013 | $84,711,000 | +10.8% | 10,628,790 | +7.3% | 0.03% | +3.6% |
Q2 2013 | $76,473,000 | – | 9,905,848 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nine Chapters Capital Management LLC | 119,700 | $254,000 | 0.43% |
GSA CAPITAL PARTNERS LLP | 1,587,756 | $3,366,000 | 0.20% |
AMERICAFIRST CAPITAL MANAGEMENT, LLC | 60,901 | $129,110,000 | 0.14% |
Acrospire Investment Management LLC | 129,480 | $274,000 | 0.11% |
SECOR Capital Advisors, LP | 410,323 | $870,000 | 0.11% |
RBF Capital, LLC | 251,421 | $540,000 | 0.08% |
Park West Asset Management LLC | 400,000 | $848,000 | 0.07% |
MACKENZIE FINANCIAL CORP | 4,687,825 | $9,938,000 | 0.06% |
CIGNA INVESTMENTS INC /NEW | 261,533 | $554,000,000 | 0.06% |
ACADIAN ASSET MANAGEMENT LLC | 5,503,285 | $11,665,000 | 0.06% |